La vendita allo scoperto per Kubient dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Kubient. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Kubient (OTC:KBNT) Azioni, Report sulle vendite allo scoperto

Kubient

Kubient Inc has developed a cloud-based software platform for real-time trading of digital, programmatic advertising. The platform allows both advertisers and publishers to use machine learning during any programmatic ad space auction.

Kubient Inc

Announced clinical trial collaboration and supply agreement with Johnson &amp; Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations
&nbsp;
Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of registrational trials for both programs in 2026

Biotech

News

General

ORIC

Oric Pharmaceuticals Announces Clinical Trial Collaboration And Supply Agreement With Johnson & Johnson To Evaluate ORIC-114 In Combination With Subcutaneous Amivantamab For The First-Line Treatment Of NSCLC Patients With EGFR Exon 20 Insertion Mutations

Ethan Allen Interiors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) reported quarterly earnings of $0.38 per share which missed the analyst consensus estimate of $0.46 by 17.39 percent. This is a 20.83 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $142.69 million which missed the analyst consensus estimate of $146.85 million by 2.83 percent. This is a 2.54 percent decrease over sales of $146.42 million the same period last year.

Earnings

Earnings Misses

Ethan Allen Interiors Q3 Adj. EPS $0.38 Misses $0.46 Estimate, Sales $142.69M Miss $146.85M Estimate

ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) raises FY2025 sales outlook from $270.00 million-$280.00 million to $281.00 million-$291.00 million vs $276.42 million estimate.

Guidance

TDUP

ThredUp Raises FY2025 Sales Guidance from $270.00M-$280.00M to $281.00M-$291.00M vs $276.42M Est

Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) affirms FY2025 sales outlook from $610.00 million-$630.00 million to $610.00 million-$630.00 million vs $611.38 million estimate.

Limbach Holdings Affirms FY2025 Sales Guidance of $610.00M-$630.00M vs $611.38M Est

IAC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) reported quarterly losses of $(2.64) per share which missed the analyst consensus estimate of $(0.93) by 183.87 percent. This is a 617.65 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $570.50 million which missed the analyst consensus estimate of $808.52 million by 29.44 percent. This is a 91.38M percent increase over sales of $624.30 the same period last year.

IAC Q1 EPS $(2.64) Misses $(0.93) Estimate, Sales $570.50M Miss $808.52M Estimate

TrueCar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUE#NASDAQ">TRUE</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.13) by 7.69 percent. This is a 100 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $44.80 million which beat the analyst consensus estimate of $44.26 million by 1.22 percent. This is a 9.13 percent increase over sales of $41.05 million the same period last year.

Earnings Beats

TRUE

TrueCar Q1 EPS $(0.12) Beats $(0.13) Estimate, Sales $44.80M Beat $44.26M Estimate

Palomar Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLMR#NASDAQ">PLMR</a>) reported quarterly earnings of $1.87 per share which beat the analyst consensus estimate of $1.59 by 17.61 percent. This is a 71.56 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $164.07 million which missed the analyst consensus estimate of $444.85 million by 63.12 percent. This is a 52.11 percent increase over sales of $107.87 million the same period last year.

PLMR

Palomar Hldgs Q1 Adj. EPS $1.87 Beats $1.59 Estimate, Sales $164.07M Miss $444.85M Estimate

ThredUp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>) sees Q2 sales of $72.500 million-$74.500 million vs $71.08 million analyst estimate.

ThredUp Sees Q2 Sales $72.500M-$74.500M vs $71.08M Est

Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) reported quarterly earnings of $1.45 per share which missed the analyst consensus estimate of $1.57 by 7.64 percent. This is a 15.2 percent decrease over earnings of $1.71 per share from the same period last year. The company reported quarterly sales of $1.67 billion which missed the analyst consensus estimate of $1.73 billion by 3.36 percent. This is a 8.05 percent decrease over sales of $1.81 billion the same period last year.

Clorox Q3 Adj. EPS $1.45 Misses $1.57 Estimate, Sales $1.67B Miss $1.73B Estimate

V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) affirms FY2025 Adj EPS guidance from $4.45-$4.85 to $4.45-$4.85 vs $2.67 analyst estimate. Affirms FY2025 sales outlook from $4.38 billion-$4.50 billion to $4.38 billion-$4.50 billion vs $4.47 billion estimate.

V2X Affirms FY2025 Adj EPS Guidance of $4.45-$4.85 vs $2.67 Est; Affirms FY2025 Sales Guidance of $4.38B-$4.50B vs $4.47B Est

Addus HomeCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.33 by 6.77 percent. This is a 17.36 percent increase over earnings of $1.21 per share from the same period last year. The company reported quarterly sales of $337.71 million which missed the analyst consensus estimate of $339.88 million by 0.64 percent. This is a 20.29 percent increase over sales of $280.75 million the same period last year.

ADUS

Addus HomeCare Q1 Adj. EPS $1.42 Beats $1.33 Estimate, Sales $337.71M Miss $339.88M Estimate

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) raises FY2025 Adj EPS guidance from $5.05-$5.20 to $5.10-$5.20 vs $5.09 analyst estimate..

AECOM Raises FY2025 Adj EPS Guidance from $5.05-$5.20 to $5.10-$5.20 vs $5.09 Est

SIBN

SI-BONE Raises FY2025 Sales Guidance from $193.50M-$195.50M to $193.50M-$197.50M vs $194.25M Est

Air Lease Q1 Adj. EPS $1.51 Beats $0.94 Estimate, Sales $738.28M Beat $710.23M Estimate

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) lowers FY2025 GAAP EPS guidance from $5.03-$5.19 to $5.00-$5.10 vs $5.01 analyst estimate..

AECOM Lowers FY2025 GAAP EPS Guidance from $5.03-$5.19 to $5.00-$5.10 vs $5.01 Est

TrueBlue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBI#NYSE">TBI</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.32) by 25 percent. This is a 1433.33 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $370.25 million which beat the analyst consensus estimate of $362.27 million by 2.20 percent. This is a 8.09 percent decrease over sales of $402.85 million the same period last year.

TrueBlue Q1 Adj. EPS $(0.40) Misses $(0.32) Estimate, Sales $370.25M Beat $362.27M Estimate

EverQuote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVER#NASDAQ">EVER</a>) sees Q2 sales of $155.000 million-$160.000 million vs $150.36 million analyst estimate.

EVER

EverQuote Sees Q2 Sales $155.000M-$160.000M vs $150.36M Est

Vitesse Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.09 by 155.56 percent. This is a 32.35 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $66.17 million which beat the analyst consensus estimate of $65.06 million by 1.71 percent. This is a 8.13 percent increase over sales of $61.19 million the same period last year.

Vitesse Energy Q1 Adj. EPS $0.23 Beats $0.09 Estimate, Sales $66.17M Beat $65.06M Estimate

SI-BONE Q1 EPS $(0.15) Beats $(0.23) Estimate, Sales $47.30M Beat $45.17M Estimate

V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.93 by 5.38 percent. This is a 8.89 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.04 billion by 2.31 percent. This is a 0.49 percent increase over sales of $1.01 billion the same period last year.

Comments

Kubient

Vendite allo scoperto

Kubient (OTC:KBNT) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO